Noèlia Téllez

Noèlia Téllez

Auto-generated profile, based on publicly available information

Noèlia Téllez

CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2020 in Diabetes
Verified
Journal Article
Closed access
PDF file
MMMeritxell Morró
Meritxell Morró
Laia VilàLaia Vilà
Laia Vilà
SFSylvie Franckhauser
Sylvie Franckhauser
CMCristina Mallol
Cristina Mallol
GEGemma Elias
Gemma Elias
ACAlba Casellas
Alba Casellas
Vitamin D deficiency has been associated with increased incidence of diabetes, both in humans and in animal models. In addition, an association between vitamin D receptor (VDR) gene polymorphisms and diabetes has also been described. However, the involvement of VDR in the development of diabetes, specifically in pancreatic β-cells, has not been elucidated yet. Here, we aimed to study the role of VDR in β-cells in the pathophysiology of diabetes. Our results indicate that Vdr expression was modulated by glucose in healthy islets and decreased in islets from both type 1 diabetes and type 2 diabetes mouse models. In addition, transgenic mice overexpressing VDR in β-cells were protected against streptozotocin-induced diabetes and presented a preserved β-cell mass and a reduction in islet inflammation. Altogether, these results suggest that sustained VDR levels in β-cells may preserve β-cell mass and β-cell function and protect against diabetes.

10 May 2011 in Endocrinology
Verified
Journal Article
Open access
NTNoèlia Téllez
Noèlia Téllez
GJGéraldine Joanny
Géraldine Joanny
JEJéssica Escoriza
Jéssica Escoriza
MVMarina Vilaseca
Marina Vilaseca
EMEduard Montanya
Eduard Montanya
Beta-Cell mass reduction is a central aspect in the development of type 1 and type 2 diabetes, and substitution or regeneration of the lost beta-cells is a potentially curative treatment of diabetes. To study the effects of gastrin on beta-cell mass in rats with 95% pancreatectomy (95%-Px), a model of pancreatic regeneration, rats underwent 95% Px or sham Px and were treated with [15 leu] gastrin-17 (Px + G and S + G) or vehicle (Px + V and S + V) for 15 d. In 95% Px rats, gastrin treatment reduced hyperglycemia (280 +/- 52 mg vs. 436 +/- 51 mg/dl, P < 0.05), and increased beta-cell mass (1.15 +/- 0.15 mg)) compared with vehicle-treated rats (0.67 +/- 0.15 mg, P < 0.05). Gastrin treatment induced beta-cell regeneration by enhancing beta-cell neogenesis (increased number of extraislet beta-cells in Px + G: 0.42 +/- 0.05 cells/mm(2) vs. Px + V: 0.27 +/- 0.07 cells/mm2, P < 0.05, and pancreatic and duodenal homeobox 1 expression in ductal cells of Px + G: 1.21 +/- 0.38% vs. Px + V: 0.23 +/- 0.10%, P < 0.05) and replication (Px + G: 1.65 +/- 0.26% vs. S + V: 0.64 +/- 0.14%; P < 0.05). In addition, reduced beta-cell apoptosis contributed to the increased beta-cell mass in gastrin-treated rats (Px + G: 0.07 +/- 0.02%, Px + V: 0.23 +/- 0.05%; P < 0.05). Gastrin action on beta-cell regeneration and survival increased beta-cell mass and improved glucose tolerance in 95% Px rats, supporting a potential role of gastrin in the treatment of diabetes. (Endocrinology 152: 2580-2588, 2011)

2 December 2004 in Gene Therapy
Verified
Journal Article
Closed access
PDF file
NTN Téllez
N Téllez
MMM Montolio
M Montolio
MBM Biarnés
M Biarnés
ECE Castaño
E Castaño
JSJ Soler
J Soler
EMEduard Montanya
Eduard Montanya

1 August 2005 in International Archives of Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
LZLaurian Zuidmeer
Laurian Zuidmeer
WLW. Astrid van Leeuwen
W. Astrid van Leeuwen
IBIlona Kleine Budde
Ilona Kleine Budde
JCJessica Cornelissen
Jessica Cornelissen
IBIngrid Bulder
Ingrid Bulder
RRRonald van Ree
Ronald van Ree
Background: Lipid transfer proteins (LTP) are stable, potentially life-threatening allergens in fruits and many other vegetable foods. The aim of this study was to clone and express recombinant apple LTP (Mal d 3), as has previously been done for peach LTP (Pru p 3) and set up quantitative tests for measuring fruit LTPs. Methods: cDNA for Mal d 3 and Pru p 3 was cloned, expressed in the yeast Pichia pastoris and the resulting proteins were purified via cation exchange chromatography. The immune reactivity of rMal d 3 was compared to nMal d 3 by RAST (inhibition), immunoblotting and basophil histamine release testing. To obtain monoclonal and monospecific polyclonal antibodies, mice and rabbits were immunized with purified nMal d 3. Results: The deduced amino acid sequence of Mal d 3 was identical to the published sequence, Pru p 3 differed at two positions (S9A and S76H). The rMal d 3 had an IgE-binding potency and biological activity close to its natural counterpart. One sandwich ELISA selectively detecting apple LTP and another cross-reactive with cherry, nectarine and hazelnut LTP were developed. In addition, a competitive RIA was developed with polyclonal rabbit antiserum and labeled nMal d 3. Conclusion: rMal d 3 (as shown before for rPru p 3) may be a useful tool for application in component-resolved diagnosis of food allergy. Assays for the measurement of LTP will increase the traceability of this potentially dangerous allergen.

13 January 2007 in Diabetologia
Verified
Journal Article
Closed access
PDF file
NTN. Téllez
N. Téllez
MMM. Montolio
M. Montolio
EEE. Estil·lEs
E. Estil·lEs
JEJ. Escoriza
J. Escoriza
JSJ. Soler
J. Soler
EMEduard Montanya
Eduard Montanya

16 June 2010 in Endocrinology
Verified
Journal Article
Closed access
ARAna B. Ropero
Ana B. Ropero
SSSergi Soriano
Sergi Soriano
ETEva Tudurí
Eva Tudurí
Laura MarroquiLaura Marroqui
Laura Marroqui
NTNoelia Téllez
Noelia Téllez
ANAngel Nadal
Angel Nadal
Atrial natriuretic peptide (ANP) and its guanylyl cyclase-A (GC-A) receptor are being involved in metabolism, although their role in the endocrine pancreas is still greatly unknown. The aim of this work is to study a possible role for the ANP/GC-A system in modulating pancreatic beta-cell function. The results presented here show a direct effect of the GC-A receptor in regulating glucose-stimulated insulin secretion (GSIS) and beta-cell mass. GC-A activation by its natural ligand, ANP, rapidly blocked ATP-dependent potassium (K(ATP)) channel activity, increased glucose-elicited Ca(2+) signals, and enhanced GSIS in islets of Langerhans. The effect in GSIS was inhibited in islets from GC-A knockout (KO) mice. Pancreatic islets from GC-A KO mice responded to increasing glucose concentrations with enhanced insulin secretion compared with wild type (WT). Remarkably, islets from GC-A KO mice were smaller, presented lower beta-cell mass and decreased insulin content. However, glucose-induced Ca(2+) response was more vigorous in GC-A KO islets, and basal K(ATP) channel activity in GC-A KO beta-cells was greatly diminished compared with WT. When protein levels of the two K(ATP) channel constitutive subunits sulfonylurea receptor 1 and Inward rectifier potassium channel 6.2 were measured, both were diminished in GC-A KO islets. These alterations on beta-cell function were not associated with disruption of glucose tolerance or insulin sensitivity in vivo. Glucose and insulin tolerance tests were similar in WT and GC-A KO mice. Our data suggest that the ANP/GC-A system may have a modulating effect on beta-cell function.